𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systemic Mastocytosis: documented pathologic response to imatinib

✍ Scribed by Russell P. Gollard; Christine Ruemmler-Fish; Diana Garcia

Book ID
114794236
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
440 KB
Volume
79
Category
Article
ISSN
0902-4441

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Response of severe systemic mastocytosis
Response of severe systemic mastocytosis to interferon alpha
✍ Butterfield πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 368 KB

Six patients with documented systemic mast cell disease were enrolled in a 1-year, phase I study to determine the possible benefits of interferon alpha-2b (IFN-alpha). IFN-alpha therapy was begun at a dosage of 0.5 million units/day (MU/day) by subcutaneous injection and increased, as tolerated, to

P109 Systemic mastocytosis with partial
P109 Systemic mastocytosis with partial response to cladribine
✍ N. Čolovič; M. Sretenovič; T. Terzič; M. Colovic; V. JuriΕ‘ič πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 62 KB

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for

Molecular framework for response to imat
Molecular framework for response to imatinib mesylate in systemic sclerosis
✍ Lorinda Chung; David F. Fiorentino; Maya J. BenBarak; Adam S. Adler; Melissa M. πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 658 KB

## Abstract Systemic sclerosis (SSc) is an autoimmune disease in which the tyrosine kinases platelet‐derived growth factor receptor (PDGFR) and Abl are hypothesized to contribute to the fibrosis and vasculopathy of the skin and internal organs. Herein we describe 2 patients with early diffuse cutan